PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30066185-3	2018	The effectiveness of budesonide/formoterol inhalation therapy in daily clinical practice, delivered via the Bufomix Easyhaler , was evaluated in patients with asthma, chronic obstructive pulmonary disease (COPD) and asthma-COPD overlap (ACO).	Budesonide	21-31	COPD	Homo sapiens	206-210	
25670896-2	2015	We aimed to derive this by analyzing data from three existing COPD clinical trials of budesonide/formoterol, formoterol, or placebo in patients with moderate-to-very-severe COPD and a history of exacerbations in the previous year.	Budesonide	86-96	COPD	Homo sapiens	62-66	
29255358-0	2017	Metabolic changes of different high-resolution computed tomography phenotypes of COPD after budesonide-formoterol treatment.	Budesonide	92-102	COPD	Homo sapiens	81-85	
27003559-3	2016	OBJECTIVE: To evaluate health care costs and utilization among COPD patients newly initiating ICS/LABA combination therapy with budesonide/formoterol (BFC) or fluticasone/salmeterol (FSC) in a managed care system.	Budesonide	128-138	COPD	Homo sapiens	63-67	
25670896-2	2015	We aimed to derive this by analyzing data from three existing COPD clinical trials of budesonide/formoterol, formoterol, or placebo in patients with moderate-to-very-severe COPD and a history of exacerbations in the previous year.	Budesonide	86-96	COPD	Homo sapiens	173-177	
24940053-6	2014	In the base case, the treatment of a patient for 1 year with budesonide/formoterol led to a saving of $499.90 ($195.10 for drugs, $193.10 for COPD hospitalizations, and $111.70 for pneumonia hospitalizations) corresponding to a -27.6% difference compared with fluticasone/salmeterol treatment.	Budesonide	61-71	COPD	Homo sapiens	142-146	
24940053-5	2014	RESULTS: The PATHOS study demonstrated a significant reduction in COPD hospitalizations and pneumonia-related hospitalizations in patients treated with budesonide/formoterol versus fluticasone/salmeterol (-29.1% and -42%, respectively).	Budesonide	152-162	COPD	Homo sapiens	66-70	
24940053-7	2014	CONCLUSION: Treatment of COPD with budesonide/formoterol compared with fluticasone/salmeterol could lead to a reduction in direct health care costs, with relevant improvement in clinical outcomes.	Budesonide	35-45	COPD	Homo sapiens	25-29	
21942463-0	2011	Comparative effectiveness of budesonide/formoterol and fluticasone/salmeterol for COPD management.	Budesonide	29-39	COPD	Homo sapiens	82-86	
23189102-14	2012	Withdrawal of budesonide for 4 weeks in the COPD phenotype resulted in FEV(1) + 1.33% (SD +- 5.71) and FVC + 1.24% (SD +- 5.32); a change of <12% in all patients.	Budesonide	14-24	COPD	Homo sapiens	44-48	
18972276-0	2008	Anti-inflammatory effects of combined budesonide/formoterol in COPD exacerbations.	Budesonide	38-48	COPD	Homo sapiens	63-67	
21128746-0	2010	Budesonide and formoterol in a single pressurized metered-dose inhaler for treatment of COPD.	Budesonide	0-10	COPD	Homo sapiens	88-92	
19228428-0	2009	Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD.	Budesonide	0-10	COPD	Homo sapiens	93-97	
19228428-12	2009	CONCLUSION: High dose budesonide/formoterol was as effective as prednisolone plus formoterol for the ambulatory treatment of acute exacerbations in non-hospitalized COPD patients.	Budesonide	22-32	COPD	Homo sapiens	165-169	
18972276-9	2008	In conclusion, budesonide/formoterol reduces sputum eosinophils and improves symptoms in the treatment of out-patient COPD exacerbations.	Budesonide	15-25	COPD	Homo sapiens	118-122	
21139721-11	2010	Nebulized budesonide may be an alternative to parental/oral prednisolone in the treatment of acute exacerbations of COPD but further studies should be done to evaluate its long-term impact on clinical outcomes after an initial episode of COPD exacerbation.	Budesonide	10-20	COPD	Homo sapiens	116-120	
21139721-11	2010	Nebulized budesonide may be an alternative to parental/oral prednisolone in the treatment of acute exacerbations of COPD but further studies should be done to evaluate its long-term impact on clinical outcomes after an initial episode of COPD exacerbation.	Budesonide	10-20	COPD	Homo sapiens	238-242	
20850023-0	2010	[Budesonide/formoterol in the treatment of COPD].	Budesonide	1-11	COPD	Homo sapiens	43-47	
20850023-1	2010	Two large, 12-month clinical trials have been performed with budesonide-formoterol in patients with stable COPD and have shown clear data on the efficacy of this combination in improving pulmonary function, symptoms and health-related quality of life and in reducing the number of exacerbations.	Budesonide	61-71	COPD	Homo sapiens	107-111	
20850023-2	2010	Before these trials, information was already available on the efficacy of both monocomponents in this disease, although the main clinical data obtained with formoterol and budesonide separately in the treatment of COPD come from the respective branches of these drugs in the two large clinical trials described in the present article.	Budesonide	172-182	COPD	Homo sapiens	214-218	
20850023-8	2010	The present review discusses the main findings on the efficacy of the combination of budesonide-formoterol in stable COPD.	Budesonide	85-95	COPD	Homo sapiens	117-121	
18829252-5	2008	Most of the drugs available for long-term management of COPD have significant effects on the frequency of exacerbations: tiotropium and salmeterol, each used alone, as well as fixed combinations of salmeterol/fluticasone or formoterol/budesonide.	Budesonide	235-245	COPD	Homo sapiens	56-60	
15936184-0	2006	Effect of formoterol/budesonide combination on arterial blood gases in patients with acute exacerbation of COPD.	Budesonide	21-31	COPD	Homo sapiens	107-111	
17251232-0	2007	The role of nebulised budesonide in the treatment of exacerbations of COPD.	Budesonide	22-32	COPD	Homo sapiens	70-74	
11874817-1	2002	Nebulized budesonide has been used successfully to treat acute asthma exacerbation, and we hypothesized that it could also be effective for exacerbations of chronic obstructive pulmonary disease (COPD).	Budesonide	10-20	COPD	Homo sapiens	196-200	
11874817-9	2002	Both budesonide and prednisolone improved airflow in COPD patients with acute exacerbations when compared with placebo.	Budesonide	5-15	COPD	Homo sapiens	53-57	
11874817-10	2002	Nebulized budesonide may be an alternative to oral prednisolone in the treatment of nonacidotic exacerbations of COPD but further studies should be done to evaluate its long-term impact on clinical outcomes after an initial episode of COPD exacerbation.	Budesonide	10-20	COPD	Homo sapiens	113-117	
11874817-10	2002	Nebulized budesonide may be an alternative to oral prednisolone in the treatment of nonacidotic exacerbations of COPD but further studies should be done to evaluate its long-term impact on clinical outcomes after an initial episode of COPD exacerbation.	Budesonide	10-20	COPD	Homo sapiens	235-239	
18046888-7	2006	Improving lung function and decreasing symptoms significantly, budesonide-formoterol combination therapy provides significant clinical improvements in COPD, despite the limited reversibility of impaired lung function in the disease.	Budesonide	63-73	COPD	Homo sapiens	151-155